End of Study report

I General information	
EudraCT number	2013-002744-89
NL number	NL45527.078.13
Title: *Bioavailability of oral ciprofloxacin tablets and suspension in pediatric cancer patients*	
Sponsor	Erasmus MC
Participating sites	☒ singlecenter: Erasmus MC only
	☐ multicenter
Principal Investigator	Dr. C.M. Zwaan

II Study status	
☐ Terminated as planned	End date of study:
☒ Early Termination	End date early termination: 01-04-2016
Reason for early termination: *Inclusion rate too slow.*	
How many participants were included at the time it was decided to terminate the study early? What are the consequences for these participants? *Two participants were included in the study; both already finished treatment at time of termination of the study.*	
What are the consequences of the early termination for the study results? *Only one patient participated for the full three study visits. The other participant terminated participation early, because he no longer fulfilled the inclusion criteria after progression of disease.* *No statistical analysis on these results is feasible.*	

III Status inclusion	
How many participants are included in the study?	Erasmus MC: 2
What is the total number of participants that needed to be included according to protocol?	Erasmus MC: 20
What is the cause for not reaching the intended number of participants? *Patients were too ill to participate in the study. A lot of patients developed mucositis, which was a contra-indication for participation, so they could not participate.*	

IV Report drafted by	
Name and function:	P. Winkler-Seinstra, Trialmanager
Date report	May 17, 2017